› Forums › General Melanoma Community › BRAFi and bone lesions
- This topic has 4 replies, 3 voices, and was last updated 8 years, 10 months ago by
Spl25.
- Post
-
- April 25, 2017 at 12:35 pm
I recently read that there is a BRAF inhibitor coming out (I think from a smaller biotech associated with BMS) that advertises that it works on osteolytic lesions (bone tumors). This would imply that the older inhibitors don't — has anyone seen any data on this or had their own bone lesions react to Dabrafenib or Vemurafenib?
- Replies
-
-
- April 25, 2017 at 1:05 pm
The article would be helpfull in order to get how it relates to Melanoma. Osteolytic lesions can occur in different types of cancer and targeted therapy is very specific to the mutation like in Melanoma where Dabrafenib and Vemurafenib are used for Braf v600 mutation. I have an article from 2016 from Onclive with Keith Flaherty a leading Melanoma Oncologist. http://www.onclive.com/conference-coverage/asco-2016/longterm-data-deepen-dabrafenibtrametinib-benefit-in-melanoma The combination of a braf and Mek inhibitor together has been the direction of researchers over the last couple of years. I haven't seen anything specific to bone mets from Melanoma in the research data. They do talk about overall tumor burden and LDH levels having some effect!!! Best Wishes !!!Ed
-
- April 25, 2017 at 1:47 pm
Thanks Ed — I couldn't find the original article anywhere. There are many studies showing that diffferent lesion sites have different response rates to IL-2, Ipi, and PD-1, but I can't find anything on BRAF. I'm BRAF mutated and have only a few sites, including bone, so obviously this is an important issue for me.
-
- April 25, 2017 at 2:50 pm
Tafinlar/Mekinist resolved a number of bone lesions for me.
-
- You must be logged in to reply to this topic.